Oct. 23 at 4:46 AM
$ACB "Fiscal Q2 2026 Expectations:
For Q2 2026, we expect to see consolidated net revenue increase year over year, driven primarily by 8% to 12% growth in our Global Medical Cannabis segment."
Q2'25 was 61,316. This could be mean a new record or at least returning to growth.
"Plant propagation net revenue is expected perform in line with traditional seasonal trends, as 25% to 35% of revenues are normal earned in the second half of a calendar year.
Consolidated adjusted gross margins are expected to increase, driven primarily by 250 to 475 basis points growth in our cannabis business, with plant propagation adjusted gross margins expected to mostly perform in line with historical trends. Improvements in our adjusted gross margins and higher global medical cannabis revenue, should lead to continued strong positive adjusted EBITDA ."
Continues in the comments...
